

Transcranial recording of electrophysiological neural activity in the rodent brain *in vivo* using functional photoacoustic imaging of near-infrared voltage-sensitive dye

1 Jeeun Kang^{1,2}, Haichong K. Zhang^{1,2}, Shilpa D. Kadam³, Julie Fedorko², Heather Valentine²,
2 Adarsha P. Malla⁴, Ping Yan⁵, Maged M. Harraz⁴, Jin U. Kang¹, Arman Rahmim², Albert
3 Gjedde^{2,6}, Leslie M. Loew⁵, Dean F. Wong^{2,4,6,7,8}, Emad M. Boctor^{1,2 *}

4 ¹ Whiting School of Engineering, Johns Hopkins University, Baltimore, MD 21218, USA

5 ² Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical
6 Institutions, Baltimore, MD 21287, USA

7 ³ Department of Neurology, Hugo W. Moser Research Institute at Kennedy Krieger, Johns Hopkins
8 Medical Institutions, Baltimore, MD 21205, USA

9 ⁴ Solomon H. Snyder Department of Neuroscience, Johns Hopkins Medical Institutions, Baltimore,
10 MD 21205, USA

11 ⁵ Department of Cell Biology, University of Connecticut Health, Farmington, CT 06030, USA

12 ⁶ Department of Neuroscience, University of Copenhagen, Copenhagen 2200, Denmark

13 ⁷ Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medical Institutions, Baltimore,
14 MD 21287, USA

15 ⁸ Department of Neurology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA.

16 * **Correspondence:**
17 Dr. Emad M. Boctor
18 eboctor1@jhmi.edu

19 **Keywords:** photoacoustic, neuroimaging, near-infrared, voltage-sensitive dye, transcranial, seizure

20 **Abstract**

21 Minimally-invasive monitoring of electrophysiological neural activities in real-time—that enables
22 quantification of neural functions without a need for invasive craniotomy and the longer time
23 constants of fMRI and PET—presents a very challenging yet significant task for neuroimaging. In
24 this paper, we present *in vivo* functional PA (fPA) imaging of chemoconvulsant rat seizure model
25 with intact scalp using a fluorescence quenching-based cyanine voltage-sensitive dye (VSD)
26 characterized by a lipid vesicle model mimicking different levels of membrane potential variation.
27 The framework also involves use of a near-infrared VSD delivered through the blood-brain barrier
28 (BBB), opened by pharmacological modulation of adenosine receptor signaling. Our normalized
29 time-frequency analysis presented *in vivo* VSD response in the seizure group significantly
30 distinguishable from those of the control groups at sub-mm spatial resolution. Electroencephalogram
31 (EEG) recording confirmed the changes of severity and frequency of brain activities, induced by
32 chemoconvulsant seizures of the rat brain. The findings demonstrate that the near-infrared fPA VSD
33 imaging is a promising tool for *in vivo* recording of brain activities through intact scalp, which would
34 pave a way to its future translation.

35

36 1 Introduction

37 The quantification and monitoring of brain function is a major goal of neuroscience and clinical
38 researches into the underlying mechanisms of the working brain (Friston, 2009; Raichle and Mintun,
39 2006). Towards this objective, several modalities have been introduced for the purpose of
40 neuroimaging; however, existing methods have limitations. Positron emission tomography (PET)
41 provides high molecular resolution and pharmacological specificity, but suffers from low spatial and
42 temporal resolution (Raichle, 1998; Vanitha, 2011). Functional magnetic resonance imaging (fMRI)
43 provides higher spatial resolution of brain activity; however, the recorded blood-oxygenation level
44 dependent (BOLD) signal has comparatively low temporal resolution and involves uncertain
45 interpretation (Berman et al., 2006; Logothetis, 2008). Optical imaging approaches have been used to
46 monitor the brain function of small animals but have limited dynamic ranges and cover only
47 superficial tissue depths because of light scattering and absorbance during penetration of biological
48 tissue (Devor et al., 2012; Hillman, 2007). These optical approaches require invasive craniotomy for
49 imaging of deeper brain region, with problematic long-term consequences such as dural regrowth,
50 greater likelihood of inflammatory cascade initiation, and lack of translational practicality to non-
51 human primate and ultimately to human studies, including those for neuropsychiatric disorders (Heo
52 et al., 2016). Near-infrared spectroscopy (NIRS) monitors brain function non-invasively in real-time
53 (~1ms) at several-mm depth for human brain, but suffers from poor spatial resolution (~1cm) at those
54 depths (Strangman et al., 2013; Torricelli et al., 2014). Therefore, minimally-invasive monitoring of
55 electrophysiological brain activities in real-time remains a task at hand in neuroimaging, with the aim
56 to quantify brain functions in the depths of brain tissue at sub-mm spatial resolution, without need for
57 invasive craniotomy or skull thinning techniques.

58 To overcome the current challenges, photoacoustic (PA) imaging has been investigated as a
59 promising hybrid modality that provides the molecular contrast of brain function with acoustic
60 transcranial penetration and spatial resolution (Wang and Hu, 2012; Wang et al., 2003). In PA
61 imaging, radio-frequency (RF) acoustic pressure is generated, depending on the thermo-elastic
62 property and light absorbance of a target illuminated by pulsed laser, and it is detected by an
63 ultrasound transducer. Based on this mechanism, several studies have presented the capability of
64 transcranial PA imaging (Li et al., 2018; Nie et al., 2012). Additionally, several PA approaches have
65 been recently applied to detect electrophysiological brain activities in both tomographic and
66 microscopic imaging configurations; Deán-Ben et al. presented *in vivo* whole brain monitoring of
67 zebrafish using real-time PA tomography of a genetically encoded calcium indicator, GCaMP5G
68 (Deán-Ben et al., 2016). Ruo et al. reported PA imaging *in vivo* of mouse brain responses to electrical
69 stimulation and 4-aminopyridine-induced epileptic seizures by means of hydrophobic anions such as
70 dipicrylamine (DPA) (Ruo et al., 2017). However, these studies used voltage sensing in the visible
71 spectral range (488nm and 530nm for GCaMP5G; 500nm and 570nm for DPA), which may not be
72 optimal for recording deep brain activity because of the optical attenuation. To address this, we
73 recently presented a novel mechanism of near-infrared cyanine voltage sensitive dye (VSD) based on
74 selective fluorescence quenching upon membrane potential variations (Zhang et al., 2017).

75 Here, we propose *in vivo* functional PA (fPA) imaging of chemoconvulsant rat seizure model with
76 intact scalp using our near-infrared cyanine VSD validated by a lipid vesicle model mimicking
77 various membrane potential levels. As a step towards minimally-invasive external neuroimaging in
78 primates and human brains, the results demonstrate that the fPA imaging of the fluorescence
79 quenching VSD mechanism is a promising approach to the recording brain activities of

80 chemoconvulsant rat model at sub-mm spatial resolution, without need for any invasive craniotomy
81 or skull thinning techniques.

82 **2 Material and Methods**

83 **2.1 fPA VSD imaging setup.**

84 An ultrasound research system was comprised by a 128-channel ultrasound linear array transducer
85 connected to a real-time data acquisition system (SonixDAQ and L14-5/38, Ultrasonix Corp.,
86 Canada). To induce the PA signals, pulsed laser light was generated by a second-harmonic (532nm)
87 Nd:YAG laser pumping an optical parametric oscillator (OPO) system (Phocus Inline, Oportek Inc.,
88 USA). The tunable range of the laser system was 690-900nm and the maximum pulse repetition
89 frequency was 20Hz. The laser pulse was fed into a fiber optic bundle delivering to bifurcated
90 outlets, each 40mm long and 0.88mm wide (Fig. 1a). The customized, 3-D printed shell fixes the
91 ultrasound probe between the outlets of the bifurcated fiber optic bundle outlets for evenly distributed
92 laser energy density in lateral direction. The bifurcated output beams were overlapped at 20mm
93 depth. The PA probe was located at around 2.2mm from bregma to obtain the cross-section of motor
94 cortexes (Fig. 1c). The distance between fPA probe and rat skin surface was 20 mm, and the resultant
95 energy density was at $3.5\text{mJ}/\text{cm}^2$, which is far below the maximum permissible exposure (MPE) of
96 skin to laser radiation by the ANSI safety standards. A wavelength of 790nm was used, at which the
97 light energy was sufficiently absorbed by the near-infrared VSD, i.e., IR780 perchlorate. Also,
98 probing at this wavelength prevented the undesired error by time-variant oxygen change, being at the
99 isosbestic point of Hb and HbO₂ absorption spectra (Fig. 1b). The bias from blood context would be
100 removed by the proposed back-end signal processing (see Section 2.9). Spatial resolution was 479.5
101 $\pm 2.7\mu\text{m}$ and $470.8 \pm 24.0\mu\text{m}$ in axial and lateral directions by applying an effective signal bandwidth
102 at 1-5MHz for envelope detection – The spatial resolution is optimized to detect the clusters of
103 contrast change generated by VSD redistribution in brain circuitries at sub-mm scale, rather than
104 differentiating individual neuronal cells (~tens of μm) or micro-vasculatures (mostly $\sim 20\mu\text{m}$ in
105 diameter, Zhang et al., 2014a) in rat brain. See the section 2.8, criteria for selecting brain region-of-
106 interest, and the supplementary information for detailed *in vivo* imaging performance. Fig. 1c
107 presents a representative cross-sectional PA image of a rat brain. The dotted white outlines for the
108 brain and motor cortex were drawn based on the rat brain atlas (Paxinos and Watson, 2014).

109 **2.2 Fluorescence quenching-based near-infrared voltage-sensitive dye.**

110 Several cyanine VSDs have been proposed as markers for real-time electrical signal detection (Treger
111 et al., 2014) and fluorescence tracking of electrical signal propagation on a heart (Martišienė et al.,
112 2016). Recently we presented the mechanism of action of a cyanine VSD for fPA neuroimaging at
113 near-infrared wavelength essential for deep transcranial neuroimaging (Zhang et al., 2017). The
114 discussed VSD redistribution mechanism proposes a suppressive PA contrast as a product of
115 fluorescence quenching when neuronal depolarization occurs. In the present study, we used the near-
116 infrared cyanine VSD, IR780 perchlorate (576409, Sigma-Aldrich Co. LLC, MO, United States) with
117 the analogous chemical structure of PAVSD800-2 in our previous study. Note that the response time
118 of the given VSD redistribution mechanism through cell membrane should be in sub-second scale as
119 presented in our previous study (Zhang et al., 2017).

120 **2.3 Lipid vesicle phantom preparation for VSD validation.**

121 The physicochemical and biophysical studies regarding the interaction of exogenous molecules with
122 a biological membrane have been extensively investigated using a single cell patch clamping (Jurkat-

123 Rott and Lehmann-Hom, 2004) or using lipid vesicle models for precise control and measurement of
124 cell membrane potential (Mazur et al., 2017; Paxton et al., 2017; Rosilio, 2018). In this study, we
125 employ the lipid vesicle model considering our VSD redistribution mechanism in a tissue-scale
126 between extracellular space and the cytoplasm of polarized cells as a function of membrane potential
127 variation. The single cell patch clamping is optimized for an individual cell, rather than the cluster of
128 cells. There is also an approach to control a cell membrane potential using valinomycin and varying
129 the external K^+ on a cell suspension, while being monitored in fluorescence or PA microscopy (Ruo
130 et al., 2017). However, this treatment for membrane potential control may affect the biological state
131 of living cells by causing them to swell and bleb in practice (Ramnath et al., 1992; Takahashi et al.,
132 1995). On the contrary, the lipid vesicle model is free from these concerns, and more consistent
133 measurements could be allowed between lipid vesicle model and translational *in vivo* experiments by
134 using our cross-sectional imaging system described in section 2.1.

135 The lipid vesicle model was prepared using the same procedure as in Zhang et al (Zhang et al.,
136 2017); 25-mg soybean phosphatidyl-choline (type II) suspended in 1mL of K^+ buffer was used as the
137 lipid vesicles. This vesicle contains 100mM K_2SO_4 and 20mM HEPES. The suspension was vortexed
138 for 10 min, and followed by 60 min of sonication within bath-type sonicator to yield a translucent
139 vesicle suspension. A Na^+ buffer was also prepared, containing 100mM Na_2SO_4 and 20mM HEPES.
140 Afterwards, 25:1, 50:1, and 100:1 K^+ gradients across vesicle membrane were established with
141 2.5 μ L, 5.0 μ L, and 10.0 μ L of lipid vesicle suspensions respectively added to 1mL of Na^+ buffers. In
142 the lipid vesicle model prepared, negative membrane potential (polarized state) was mimicked by
143 adding 2.5 μ L of 10 μ M valinomycin—a K^+ specific ionophore, thereby K^+ ions were transported from
144 inside to outside of vesicle membranes. On the other hand, 2.5 μ L of 1mM gramicidin, a nonspecific
145 monovalent cation ionophore, enabled Na^+ cations to move from outside to inside of vesicle
146 membranes to short circuit the membrane potential (depolarized state). From these controls, our near-
147 infrared VSD positively charged can move in and out through the membrane, leading to the change
148 in fluorescence quenching depending on their aggregation status. From this lipid vesicle model, we
149 expected the logarithmic change in membrane potential levels based on the Nernst equation (Archer,
150 1989): -83mV, -102mV, and -120mV. This will yield a corresponding suppression in PA intensity.
151 The quantum yields of the VSD in depolarized states (Φ'_F) were estimated based on the equations in
152 our previous literature (Eqs. 8 and 9 in (Zhang et al., 2017)).

153 2.4 Animal preparation.

154 For the proposed *in vivo* experiments. 8-9-week-old male Sprague Dawley rats weighing 275-390g
155 were used (Charles Rivers Laboratory, Inc., MA, United States). The use of animals for the proposed
156 *in vivo* protocol was approved by the Institutional Research Board Committee of Johns Hopkins
157 Medical Institute (RA16M225). All animals were anesthetized by intraperitoneal injection with a
158 ketamine (100mg/ml) / xylazine (20mg/ml) cocktail. (3:1 ratio based on body weight at 1ml/kg). The
159 hair was shaved from the scalp of each rat for better optical and acoustic coupling. The head of the
160 anesthetized rat was fixed to a stable position using a standard stereotaxic device. This fixation
161 procedure was required to prevent any unpredictable movement during the fPA recording.

162 2.5 Chemoconvulsant seizure induction.

163 Penetylenetetrazole (PTZ), a gamma-aminobutyric acid (GABA) A receptor antagonist was used to
164 induce acute seizures in the animals (Löscher, 2017). PTZ suppresses the inhibitory effects of
165 GABA, thus leading to generation of synchronized depolarizations of neurons in form of epileptiform
166 discharges and seizures (Bradford, 1995). To induce global episodic acute seizures in rat brain, an
167 intraperitoneal (IP) injection of PTZ (45mg/ml) was utilized based on the animal's body weight in a

168 volume of 1ml/kg. Subsequent doses were given if no acute motor seizure was observed in 5-10 min
169 after the first PTZ injection. Generally, 1-2 doses were sufficient to induce the motor seizures in our
170 experiments.

171 **2.6 Pharmacological treatment for VSD delivery into blood-brain-barrier.**

172 The lumen of the brain microvasculature consists of brain endothelial cells, and the blood-brain
173 barrier (BBB) is comprised of their tight junctions to control the chemical exchange between neural
174 cells and cerebral nervous system (CNS). In this study, the penetration through BBB were achieved
175 with a pharmacological method using FDA-approved regadenoson (Lexiscan, Astellas Pharma US,
176 Inc. IL, United States). This modulates the Adenosine receptor signaling at BBB layer (Carman et al.,
177 2011). The dosage and IV administration method indicated by the manufacturer was utilized: A
178 volume of 150 μ l of the standard concentration of 0.08mg/1ml was given to each animal regardless of
179 the weight, followed by 150 μ l flush of 0.9% sodium chloride for injection. The experimental
180 protocol was designed based on the pharmacological assumption that the VSD delivery through BBB
181 would occur during the Lexiscan's biological half-life, i.e., 2-3 min. The efficiency of the
182 pharmacological BBB opening was evaluated by the frozen-section histopathological analysis with
183 near-infrared fluorescence microscopy. Three different groups were compared in this study: (1)
184 Negative control: VSD-/Lexiscan-; (2) Control: VSD+/Lexiscan-; (3) BBB opening:
185 VSD+/Lexiscan+.

186 **2.7 *In vivo* experimental protocol.**

187 Fig. 1d shows the detailed protocol for VSD control, seizure control, and seizure groups. Note that
188 each data acquisition was performed for 10 min to cover the biological half-life of Lexiscan for VSD
189 delivery (2-3 min). Each dosing protocol of Lexiscan and VSD was as follows: Through the jugular
190 vein catheter port located in the neck, 150 μ l of Lexiscan 0.4mg/5ml concentration was injected, and
191 300 μ l of VSD was subsequently administrated at 0.1mg/ml concentration, followed by 150 μ l of
192 saline solution flush. The seizure control ($n = 2$) and seizure groups ($n = 4$) were designed to
193 distinguish the chemoconvulsant effects on neural activity: both groups received VSD and Lexiscan,
194 but only seizure group had IP injection of PTZ (45mg/ml/kg). The induction of seizure was
195 confirmed by monitoring motor seizure, and another dose of PTZ was injected when no motor
196 seizure was observed in 5-10 min. In particular, the success of the rat seizure model was determined
197 by the behavioral observation to identify the tonic-clonic movements in whisker, fore and hind-limbs
198 of the anesthetized rat. Once the seizure is developed, the behavioral seizure activity was maintained
199 for entire time domain (0 – 10 min) in all the data sets presented in this paper. The VSD control
200 group ($n = 2$) was designed to validate the inability of Lexiscan and PTZ to generate any bias on the
201 quantification of fPA VSD responses. In this group, the baseline was obtained with the Lexiscan
202 dosage, and subsequent data set was obtained during the chemoconvulsant seizure with secondary
203 Lexiscan dosage without VSD.

204 **2.8 Criteria for selecting region-of-interest.**

205 The coronal sections of interest were selected to include motor cortices at bregma 2.2mm, at which
206 the synchronized depolarizations of neurons are confirmed by behavioral observation of motor
207 seizure (See Movie 1). In the superficial depth, the signals from superior sagittal sinus (SSS) and
208 superior cortical veins (SCV) are dominant as they contain abundant blood context. Skin surface was
209 less obvious as the melanin contents, a major absorber in scalp, has low absorbance at near-infrared
210 range (Jacques and Prahl, 2013). Since the intracerebral vasculatures in rat brain (mostly <20- μ m in
211 diameter, Zhang et al., 2014a) is narrower than the spatial resolution available, i.e., ~500 μ m, we used

212 the relative position to SSS and brain atlas by Paxinos as a criteria to localize brain tissue region
213 (Paxinos and Watson, 2014). In axial direction, there are four layers between SSS and brain tissue.
214 The SSS is in the middle of dura mater (300 μ m) which is above the arachnoid (75 μ m), subarachnoid
215 space (750 μ m), and pia mater (75 μ m) layers covering a rat brain (Nowak et al., 2011). Therefore, the
216 expectable distance between SSS and brain atlas map should be 1,050 μ m, and motor cortex is
217 extended at 3-4mm from the brain surface (bregma 2.2–3.2mm (Paxinos and Watson, 2014)). From
218 the anatomical criteria, entire brain region was selected as the region-of-interest (ROI) to reject any
219 subjective bias.

220 2.9 Normalized time-frequency analysis.

221 Fig. 2 demonstrates the flow chart of our normalized time-frequency analysis method based on a
222 short-time Fourier transform (STFT) to detect the suppressive VSD contrast in rat brain. The detailed
223 task in each step is as following:

- 224 - **Step 1: Reconstruction of PA image sequence** using a delay-and-sum beamforming for the
225 radio-frequency (RF) channel data averaged for 2-sec duration (40 frames) with 0.25-sec interval
226 (5 frames interval). The signal envelope was detected in the bandwidth 1 - 5MHz. This led to 4Hz
227 refreshing rate, and enables the frequency analysis up to 2Hz with high sensitivity. The higher
228 imaging speed would be redundant considering slow VSD response in sub-second scale;
- 229 - **Step 2: High-pass filtering** at 0.2Hz cutoff frequency in temporal direction at each pixel of
230 envelope-detected PA cross-section image to exclude the seizure-induced hemodynamic changes
231 extended in few tens of seconds, which would extend up to 0.1Hz in frequency domain (Sigal et
232 al., 2016);
- 233 - **Step 3: Short-time Fourier transform (STFT)** at each image pixel point with an analysis
234 window across 40 temporal samples. $PA(t, f)$ denotes a STFT spectrogram at a time point t ;
- 235 - **Step 4: Frequency-domain normalization** by the averaged intensity at low-frequency band f_L
236 (i.e., 0.3-0.5Hz) at each t : $PA(t, f) = \log_{10}(PA(t, f) / E\{PA(t, f)\}_{f_L})$, where $PA(t, f)$ and $PA(t, f)$ are
237 the PA sequence before and after the normalization. This procedure is to fairly evaluate the
238 amount of suppression at high-frequency range (0.5-2Hz) relative to the reference intensity at f_L .
239 The logarithm procedure is to present the PA intensity in negative decibel level with an emphasis
240 on suppressive PA contrast;
- 241 - **Step 5: Baseline normalization:** $PA(t, f) = PA(t, f) / PA_0(f)$, in which the $PA_0(t, f)$ is the reference
242 spectrum time-averaged for 5-10-min period in the baseline phase. In this step, the suppressive
243 VSD contrast is converted into positive contrast in $PA(t, f)$ – More suppressive contrast relative to
244 the baseline would yield higher $PA(t, f)$;
- 245 - **Step 6: fPA quantification of VSD response:** A fPA VSD response at each pixel is defined by a
246 $PA(t, f)$ projected over 0.5-2Hz range: $(E\{PA(t, f)\}_{f=0.5-2\text{Hz}} - 1) \times 100$. This reflects how much
247 fractional suppression have produced compared to the reference STFT spectrum. Repeat steps 1 –
248 6 until all the pixels in brain cross-section are processed.

249 In our signal processing, high-pass filtering (Step 2) performs an important role to reject seizure-
250 induced change in hemodynamics. All the gradual increasing bias and instantaneous changes in blood
251 context would not be account in the outcome (Fig. 2). On the other hand, the electrophysiological
252 seizure activity would be broadly extends from few Hz to several tens of Hz (Siemen et al., 2011), at
253 which the suppressive VSD mechanism in fPA imaging will be presented.

254 2.10 EEG validation of neural seizure activity.

255 To obtain the EEG records of electrical spike discharges that originated from brain tissue, sub-dermal
256 scalp EEG recording electrodes were located at the corresponding locations on motor cortex (See the
257 Fig. 9a), the schematic of the rat cranium (three electrodes, 1 recording and 1 reference over motor
258 cortex, 1 ground electrode over rostrum). Silver wire sub-dermal electrodes made for use in humans
259 (IVES EEG; Model #SWE-L25-MA, IVES EEG solutions, USA) were implanted sub-dermally,
260 which records with a low, steady impedance, i.e., 5K Ω . Electrodes were fixed in position with
261 cyanoacrylate adhesive (KrazyGlue, USA). The EEG signal at motor cortex was recorded with the
262 identical preparation procedures in fPA imaging including animal preparation, administration of
263 VSD, Lexiscan, and PTZ, time duration for recording, and interval between sequences in the
264 protocol. Data acquisition was done using Sirenia software (Pinnacle Technologies Inc., Kansas,
265 United States) with synchronous video capture. Briefly, the data acquisition and conditioning system
266 had a 14-bit resolution, sampling rates of 400Hz, high pass filters of 0.5Hz and low pass filters of
267 60Hz. The files were stored in .EDF format and scored manually for protocol stages using real time
268 annotations added to the recording during the experiments. EEG power for 10 sec epoch displays
269 within the scoring software package was done using an automated module in Sirenia. Further details
270 of our proposed EEG data acquisition and analysis used in this study are as presented in previous
271 studies (Adler et al., 2014; Johnston et al., 2014).

272 3 Results

273 Fig. 3 presents the experimental results for a lipid vesicle model in various K⁺ gradient levels. The
274 membrane potential of soybean lipid vesicle model is manipulated by the valinomycin and
275 gramicidin, by which the quantum yield change of VSD could accordingly triggered (Fig. 3a). From
276 the spectrophotometric and spectrofluorometric measurements (Fig. 3b), the fractional change in
277 fluorescence emission of the depolarized state over the polarized state were 19.70%, 61.63%, and
278 69.69% at -83mV, -102mV, and -120mV of membrane potential levels, respectively (i.e., 25-, 50-,
279 and 100-fold K⁺ gradient levels), while preserving a comparable level of absorbance: i.e., 0.07%,
280 0.70%, and 0.21% of fractional changes, respectively. The fPA intensity change presented in Fig. 3c
281 indicates the corresponding suppressive contrast in depolarized state from a polarized state: -
282 4.91 \pm 4.00%, -11.49 \pm 2.00%, and -14.68 \pm 1.41% at -83mV, -102mV, and -120mV of membrane
283 potential levels ($p < 0.005$). The expectable fPA contrast derived from the lipid vesicle experiments
284 is -12.24 \pm 1.18% / 100 mV. The quantum yield changes according to the given K⁺ gradient levels
285 were also estimated based on the theoretical model in our previous literature (Zhang et al., 2017). The
286 median value in the estimated quantum yield range for each K⁺ gradient level presents a
287 proportionally-increasing trend as depolarized (Fig. 3d). Note that the non-specific quantum yield at
288 25-fold K⁺ gradient is due to a limited sensitivity to differentiate the subtle membrane potential
289 variation – The specificity of the estimation becomes proportionally improved as more K⁺ gradient is
290 given.

291 With the validated VSD mechanism, we conducted the *in vivo* validation for the transcranial fPA
292 sensing of electrophysiological neural activity in the rat brain. The fPA probe imaged the coronal
293 cross-section at bregma 2.2mm to cover the motor cortex where the seizure was confirmed by
294 behavioral observation. Fig. 4a shows the fPA VSD response maps projected for 10 min in each
295 group to compare the activated brain regions among groups. All images have same range in the fPA
296 VSD response, i.e., 0.00–3.00. In the seizure group, the chemoconvulsant seizure induced substantial
297 VSD responses, while the control groups revealed limited activity in cortical region throughout
298 comparison phase. Fig. 4b compares fPA VSD responses in each group projected within whole brain
299 region. Note that they were normalized by the mean value derived from the seizure group. As a
300 result, the seizure group scored 81.3% and 97.9% more fPA VSD response than those in VSD control

301 and seizure control groups. The seizure group indicated significant difference in comparison to the
302 projection of the control groups: 1.00 ± 0.31 ($n = 4$) vs. 0.53 ± 0.10 ($n = 4$); $p < 0.05$.

303 The appropriate VSD delivery into brain tissue was confirmed by the histopathological analysis on
304 the harvested rat brains (Fig. 5). Three different groups were compared: (1) negative control group,
305 VSD-/Lexiscan-; (2) control group, VSD+/Lexiscan-; and (3) BBB opening group, VSD+/Lexiscan+.
306 From the ROIs indicated at cortical regions, the substantially-enhanced VSD uptake have been
307 identified on the BBB opening group compared to that shown in the control group: 121.03 ± 7.14 vs.
308 79.19 ± 2.16 ; $p < 0.001$. The negative control group did not present any distinguishable fluorescence
309 contrast as anticipated. The result presents the effectiveness of BBB opening based on
310 pharmacological adenosine receptor signaling modulation by regadenoson, which is consistent with
311 our recent fluorescence validation *in vivo*. (Pak et al., 2018)

312 We validated the chemoconvulsant-induced seizure activity in the identical *in vivo* protocol with
313 EEG recording. Using a well-established model of chemoconvulsant-induced *status epilepticus*, we
314 replicated the classic evolution of chemoconvulsant-induced *status epilepticus* using PTZ (Fig. 6)
315 (Löscher, 2017). These evolutions as related to bursts of synchronized neural activity *in vivo* were
316 assessed by EEG using the experimental protocols mirrored from that of fPA imaging experiments.
317 We recorded vEEGs of seizure inductions using PTZ (45mg/kg IP injections) in anesthetized rats.
318 EEG baseline recording continued until a stable seizure induction profile (i.e., continuous burst
319 discharges indicating synchronized neuronal depolarization-related action potentials) was recorded
320 using sub-dermal EEG scalp electrodes. The seizure activity in EEG was associated with tonic-clonic
321 movements in the fore- and hind-limbs of the anesthetized rats, indicating motor cortex involvement
322 (Movie 1). The PTZ evolution of status on EEG did not alter with VSD treatment.

323 4 Discussion

324 Here, we present comprehensive characterization of our near-infrared cyanine VSD mechanism using
325 the lipid vesicle model, and a transcranial fPA VSD imaging of brain activity *in vivo* at sub-mm
326 spatial resolution using rat seizure model with intact scalp. The near-infrared cyanine VSD, IR780
327 perchlorate, clearly revealed the VSD mechanism-of-action for different amount of membrane
328 depolarization with the fractional contrast at $-12.24 \pm 1.18\%$ / 100 mV (Fig. 3). Also, the proof-of-
329 concept *in vivo* validation study demonstrated that the non-invasive fPA VSD imaging without any
330 invasive craniotomy or skull thinning procedures is capable of differentiating the generalized
331 depolarization events in the seizure group from those in control groups (Fig. 4), which also well
332 agreed with EEG validation (Fig. 6). Normalized time-frequency analysis method successfully
333 extracted suppressive VSD contrast in coronal cross-section of rat brain over the increasing
334 hemodynamic change with chemoconvulsant seizure using PA intensity envelope-detected in 1-
335 5MHz bandwidth. In addition, the pharmacological enhancement of VSD delivery into rat brain by
336 increased permeability of the BBB was confirmed by histopathological validation (Fig. 5). These
337 results demonstrate the feasibility of transcranial fPA VSD imaging at sub-mm spatial resolution
338 without any needs for highly-complex tomographic system and/or invasive procedures required in
339 fPA imaging approaches at visible wavelength range.

340 The pixel-by-pixel correlation between fPA VSD response and the fractional PA intensity
341 provided interesting perspectives (Fig. 7). In seizure group, the pixels presenting 2.25 to 3.00 of the
342 fPA VSD response projected over 10 min indicated -20.94% of suppressive PA contrast, which
343 corresponds to the proposed VSD mechanism. Interestingly, not all the suppressive changes in PA
344 intensity was converted into high fPA VSD response, which also validate a role of the normalized

345 time-frequency analysis method to isolate the VSD response from the hemodynamic changes.
346 Otherwise, the control groups did not present high fPA VSD response at the cortical regions, whereas
347 the seizure was also confirmed by behavioral observation in VSD control group. On the other hand, it
348 would be also noteworthy that there was a case in seizure control group with unexpectedly localized
349 yet high fPA VSD response at the primary somatosensory cortex region according to the rat brain
350 atlas (the second rat case in Fig. 4). We hypothesize that neural activity might be real as the
351 ketamine-xylazine does enable spontaneous and well as evoked cortical activity in anesthetized
352 brains especially in periods after > 30 min following induction (Goss-Sampson and Kriss, 1991;
353 Ordek et al., 2013). *In vivo* experimental protocol will be further regulated in our future investigation
354 to reject any sensory interferences.

355 The potentially confounding factors for the *in vivo* experiments need to be carefully considered
356 and eliminated. The change in CBV during chemoconvulsant seizure can generate proportional
357 change of PA intensity that can be misinterpreted as the VSD response (Goldman et al., 1992; Hoshi
358 and Tamura, 1993; Nehlig et al., 1996). Zhang et al. suggested that time frame of the CBV change
359 induced by chemoconvulsant seizure model: The time length of gradual CBV change from PTZ
360 injection to seizure onset was ~2 min on average (Zhang et al., 2014b). However, it was sufficiently
361 covered by ~10 min of stabilization phase in our *in vivo* protocol (Fig. 1d). There is also an
362 instantaneous hemodynamic change, but it extends in tens of seconds, and was rejected using high-
363 pass filtering as described in the method section. Moreover, potential interference due to heart
364 beating would not affect the results, as every individual fPA frame was compounded for two seconds
365 that include 11–16 heart cycles of a rat (typically 5.5–8 beats per second).

366 The stability of stereotaxic fixation against the induced motor seizure was also investigated. The
367 counter-hypothesis of this concern was an abrupt disorientation of rat brain due to motor seizure that
368 will induce instantaneous decorrelation between adjacent PA frames. Also, based on the behavioral
369 observation during seizure, we anticipated the decorrelation within a sub-second time scale, if it
370 happened. For these hypotheses, we calculated the cross-correlation maps throughout PA frames
371 obtained from 2 min to 8 min (1920 frames, 240 frames/min). Three different time intervals for
372 decorrelation calculation were tested: 0.25 sec, 0.5 sec and 1 sec, which respectively correspond to 1,
373 2 and 4 frame intervals (Fig. 8). From the minimal correlation projection (MCP) map projected in
374 entire temporal direction, motor seizure did not yield a significant decorrelation in the adjacent PA
375 images when comparing to normal condition for the given time period. Even with 1 sec of interval,
376 baseline and seizure phases present consistent minimal correlation value in the brain tissue region:
377 0.53 ± 0.04 vs. 0.54 ± 0.04 , respectively. Therefore, the interference by motor seizure could be rejected
378 as potential cause of artifacts in the results.

379 Toxic CNS effects of VSD is another factor that alters brain activity. We tested our protocols with
380 varying VSD concentration in rats as a direct application to the cortex. Rats were anesthetized with
381 IP injection to ketamine/xylazine and a cranial window was made over the right motor cortex. After
382 recording a baseline EEG in the rat for 10-min duration with the craniotomy, the follow-on EEG
383 recording continued to record EEG following application of increasing concentrations of vehicle
384 alone and VSD + vehicle for the same duration of EEG recordings (i.e., 10 min) allowing
385 comparisons of EEG responses to each increasing gradient of VSD on cortical activity as compared
386 to baseline EEG signature in the same rat. Results for VSD with cortical application with cranial
387 windows used in six male rats yielded reliable and reproducible EEG signatures for each
388 concentration (Fig. 9). This protocol identified that VSD concentrations had no effect in altering the
389 baseline EEG in the same rat, indicating no toxic effect on cortical circuit function. Direct cortical
390 application with 100X VSD resulted in significant EEG background suppression in 4/6 rats,

391 indicating that the certain concentrations of VSD could alter baseline circuit function in the motor
392 cortex. This EEG suppression was recovered to baseline over the 10-min recording period, indicating
393 that the transient effect from the time of application as the 100X VSD either diluted or cleared out of
394 the focal application zone over the 10-min period. We reject the toxic CNS effects of VSD as we
395 used 10X concentration based on this result.

396 We plan a number of follow-up efforts to further advance the concept. We will further regulate the
397 experimental protocol, including possible visual or audible perceptions for rats during the
398 experiments, and also collect more *in vivo* data sets. In addition, there would be several
399 improvements in imaging system: using 2-D PA probe would provide the most reliable setup as it
400 enables the absolute positioning of specific brain parts. Also, the sensing speed of our current fPA
401 imaging system would be improved. Current fPA sensing speed is limited to 4 frames per second to
402 obtain sufficient transcranial signal sensitivity in the deep brain cortex region. This speed may limit
403 its applicability in research, as it is well known that resting electrophysiological neural activity
404 ranges up to several tens of Hz (e.g., delta: 1–4Hz; theta: 4–8Hz; alpha: 8–13Hz; beta: 13–30Hz;
405 gamma: 30–80Hz). Having another dimension in spectral dimension would be beneficial to quantify
406 the VSD response and hemodynamic changes at the same time. Successful improvements will
407 substantially increase the capability to understand brain circuit functionality in real-time using the
408 proposed fPA imaging technology.

409 To pave the way to its translation, we will further evaluate its feasibility in larger-scale brain
410 models. Localized stimulation and detection of fPA VSD response in deeper brain regions of rodent
411 animal have been our first step; We recently presented a success to monitor the activities in
412 hippocampus at ~5mm depth through intact scalp in rat animal (Kang et al., 2018b). In this study, a
413 dentate gyrus (DG) gatekeeping function was selectively stimulated by focal N-methyl-D-aspartate
414 (NMDA) infusion using a reversed microdialysis, while collecting dialysate samples by a forward
415 microdialysis. On the other hand, the fPA VSD neuroimaging in sagittal direction was concurrently
416 performed at the contralateral side of the microdialysis. The configuration enabled the quantification
417 of an extracellular glutamate concentration as a marker of excitatory neurotransmittance focally
418 manipulated at the DG and its correlation to fPA VSD response. As a result, we presented the
419 positive correlation of fPA VSD response to the dose-dependent changes of extracellular glutamate
420 concentration at the hippocampal circuitry. We will also step forward to use the larger brain models
421 of porcine and non-human primate animals, which will provide practical size and anatomy of brain as
422 well as thicker skull and scalp when compared to humans. We also achieved an encouraging progress
423 to obtain the sufficient sensitivity on the physiological hemodynamic changes through thick scalp
424 and skull layers intact with 5mJ/cm² energy density (Kang et al., 2018a).

425 Having near-infrared VSD with a faster time response is definitely in interest for our further
426 studies, and we are working on to secure better kinetics and absorbance. It would be largely
427 beneficial for more profound level of neuroscientific researches. For example, evaluating
428 instantaneous responses to various controlled stimulations at a specific neural compartment would
429 also requires the faster VSD. However, use of such faster VSD would necessitate much higher
430 standard in fPA imaging sensitivity to overcome background noise caused by various factors such as
431 laser energy fluctuation, heart beating, and other biological variations, etc. Therefore, faster laser
432 system with sufficient energy density will be needed to secure a sufficient transcranial imaging
433 sensitivity. In addition, employing advanced image quality enhancing algorithms such as deep
434 learning-based filtering or adaptive beamforming would be also investigated.

435 Even though we succeed to detect brain activities at the VSD concentration below the threshold
436 interfering brain activity (Fig 9), there have been no long-term and comprehensive toxicity study.
437 The toxicity and biodegradability of our VSD is an important issue that deserves further evaluation.
438 However, we are optimistic about this issue as the metabolic products of IR780 perchlorate should be
439 very similar to ICG, FDA-approved near-infrared cyanine dye, because they are basically comprised
440 by same chromophore. This strongly suggests its biocompatibility of our cyanine VSD. We will
441 further prove our hypothesis in our future works.

442 Furthermore, the integration of localized neural stimulation methods to our fPA imaging will
443 allow us to substantially elevate our understanding on how brain respond to a controlled stimuli
444 (Lewis et al., 2016). The integration of the proposed fPA VSD imaging with a transcranial
445 neuromodulation method may have a huge impact on the neuroscientific and clinical efforts by
446 enabling the breakthrough beyond the passive brain investigation. In addition, there could be
447 additional benefits on non-pharmacological BBB opening with a specific modality such as focused
448 ultrasound (Chu et al., 2015; Tufail et al., 2011).

449 **5 Conflict of Interest**

450 The authors declare that the research was conducted in the absence of any commercial or financial
451 relationships that could be construed as a potential conflict of interest.

452 **6 Author Contributions**

453 J. K. planned and conducted lipid vesicle and *in vivo* experiments, analyzed the data, and wrote the
454 first draft; H. K. Z. conducted lipid vesicle experiments and analysis; S. D. K. conducted *in vivo* EEG
455 measurements and analysis; J. F. and H. V. prepared animal model and conducted *in vivo*
456 experiments; P. Y. and L. M. L. provided VSD compound with the guidance for its *in vivo* use. A. P.
457 M. and M. M. H. conducted histopathological validation of VSD delivery to brain; J. U. K. funded
458 and participated in the development of the current fPA imaging system; D. F. W., A. R. and A. G.
459 provided the original funding for the *in vivo* experiments; E. M. B led the development, system
460 specification, and funding of the current fPA VSD imaging system. He also confirmed the final
461 manuscript. All authors edited the manuscript.


462 **7 Funding**

463 Financial support was provided by the NIH Brain Initiative under Grant No. R24MH106083-03 and
464 the NIH National Institute of Biomedical Imaging and Bioengineering under Grant No.
465 R01EB01963. Jeeun Kang, Ph.D. is supported by Basic Science Research Program through the
466 National Research Foundation of Korea (NRF) funded by the Ministry of Education
467 (2018R1A6A3A03011551).

468 **8 Acknowledgments**


469 Authors thank Dr. Abhinav K. Jha for proof reading the manuscript and providing helpful comments.
470 Also, authors thank Drs. Diane S. Abou and Daniel L. J. Thorek for providing equipment and
471 facilities for lipid vesicle experiments with helpful comments.

472 **Figures**




473

474 Fig. 1. Transcranial VSD sensing setup using fPA imaging system: (a) schematic diagram of experimental setup; (b)
 475 absorbance spectra of VSD, deoxy- and oxy-hemoglobin. Dotted line indicates the wavelength used in *in vivo*
 476 experiment, i.e., 790nm; (c) cross-sectional PA image of cerebral cortex; (d) *in vivo* experimental protocol. SSS: Superior
 477 sagittal sinus; SCV: Superior cortical veins. L-MC/R-MC: left/right motor cortex. Note that the outlines for brain and
 478 motor cortex in Fig. 1c was drawn based on the rat brain atlas (Bregma 2.2mm) (Paxinos and Watson, 2014). The success
 479 of seizure induction on motor cortex was confirmed by tonic-clonic movements in the fore and hind-limbs of the
 480 anesthetized rat during the experiments (See Movie 1).




481

482 Fig. 2. Flow chart of the short-time Fourier transform (STFT)-based normalized time-frequency analysis method. The
 483 dotted contour is boundary of brain tissue drawn based on rat brain atlas. White bar indicates 1 mm.



484


485 Fig. 3. VSD characterization using a lipid vesicle model. (a) Schematic diagram of a lipid vesicle model. (b) Fractional
 486 changes of the spectrophotometric and spectrofluorometric measurements in the polarized (black) and depolarized (blue)
 487 states. (c) PA intensity spectrum at 25-, 50-, and 100-fold K⁺ gradients and fractional changes at 790 nm ($p = 0.055$,
 488 0.010, and 0.002) between polarized and depolarized states for 25-, 50-, and 100-fold K⁺ gradients, respectively. (d) The
 489 estimated quantum yield change for each K⁺ gradient level (Zhang et al., 2017). The median values were presented in the
 490 estimated quantum yield range for each K⁺ gradient level.



491


492 Fig. 4. *In vivo* transcranial fPA VSD imaging for seizure, VSD control, and seizure control groups: (a) The fPA VSD
 493 response maps in each group. Note that each column indicates an individual rat included in each group; (b) The mean and
 494 standard deviation of the fPA VSD response in each group. The region-of-calculation for each rat was extended to an
 495 entire brain region. The representative examples in ROI selections and corresponding fractional PA intensity change map
 496 are presented in Fig. S2 in the supplementary information.

497




498

499 Fig. 5. Histopathological analysis on negative control (VSD-, Lexiscan-), control (VSD+, Lexiscan-), and BBB opening
500 (VSD+, Lexiscan+) groups. Scale bar indicate 1 mm.




501

502 Fig. 6. Evolution of EEG signal in the *in vivo* protocol identical to transcranial fPA imaging: (a) Representative EEG
503 traces recorded from rat motor cortex before and during induction of status epilepticus using chemoconvulsant PTZ. The
504 baseline and control EEG traces represent EEG activity in an anesthetized rat (see methods) with and without
505 IR780+lexiscan given at the dosage found to not alter baseline EEG activity in the pilot study. PTS seizure induction
506 proceeded in classical style described previously wherein episodic epileptiform burst activity evolved into status
507 epilepticus with intermittent occurrence of seizures and stable interictal activity. (b) EEG spectral quantitation of the EEG
508 recording done every 10 sec epoch during the EEG showed the expected progression in EEG power associated with
509 evolution of the PTZ induced status epilepticus. Time line of PTZ injections indicated with arrows. Expanded EEG traces
510 on top show the uniform epileptiform discharges after following second PTZ injection and below a seizure event
511 followed of post-ictal suppression indicating the termination of that event.




512

513 Fig. 7. Correlation of fPA VSD response to the fractional change in PA intensity between baseline and comparison
514 phases. Pixels were categorized to four bins of distinct fPA VSD response ranges: 0 – 0.25, 0.25 – 0.5, 0.5 – 0.75, and
515 0.75 – 1.



516

517 Fig. 8. Minimal correlation projection (MCP) image using cross-correlation coefficients with varying time interval, i.e.,
 518 0.25 sec, 0.5 sec, and 1 sec, which respectively corresponds to 1, 2, 4 frame intervals with the imaging rate at 4 frames
 519 per second. (a) region of interest for the inter-frame cross-correlations, (b) MCP images of baseline (PTZ-, VSD-) and
 520 seizure groups (PTZ+, VSD-) for brain tissue region. (c) Cross-correlation coefficient for varying time intervals. Scale
 521 bar indicate 1 mm.



522

523 Fig. 9. VSD toxicity study using EEG recordings during direct cortical applications using a cranial window in rats. (a)
 524 Schematic of experimental protocol. A rectangular cranial window drilled under anesthesia overlying unilateral motor
 525 cortex. Duramater was kept intact. Following craniotomy, a small window was made in duramater without traversing
 526 blood vessels. (b) EEG recording of baseline brain activity under anesthesia was followed by using a hamilton micro
 527 sssyringe to apply increasing concentrations of IR780 directly to the cortical surface via window made in duramater. Base

528 EEG remained unaltered at lower concentrations but showed significant background suppression after applying a 100X
529 solution. This study allowed us to determine the concentration of IR780 10X for all PA experiments. (c) EEG power
530 spectral quantification for every 10-sec epoch of EEG over the duration of the recording confirmed EEG suppression with
531 the 100X dose.

532

533 **References**

- 534 Adler, D. A., Ammanuel, S., Lei, J., Dada, T., Borbiev, T., Johnston, M. V., et al. (2014). Circadian
535 cycle-dependent EEG biomarkers of pathogenicity in adult mice following prenatal exposure to
536 in utero inflammation. *Neurosci Res* 275, 305–313. doi:10.1016/j.neuroscience.2014.06.022.
- 537 Archer, M. D. (1989). *Electrochemistry, Past and Present*. eds. J. T. Stoke and M. V. Orna
538 Washington, DC: American Chemical Society doi:10.1021/bk-1989-0390.ch008.
- 539 Berman, M. G., Jonides, J., and Nee, D. E. (2006). Studying mind and brain with fMRI. *Social*
540 *cognitive and affective neuroscience* 1, 158–161. doi:10.1093/scan/ns1019.
- 541 Bradford, H. F. (1995). Glutamate, GABA and epilepsy. *Progress in Neurobiology* 47, 477–511.
542 doi:10.1016/0301-0082(95)00030-5.
- 543 Carman, A. J., Mills, J. H., Krenz, A., Kim, D.-G., and Bynoe, M. S. (2011). Adenosine receptor
544 signaling modulates permeability of the blood-brain barrier. *Journal of Neuroscience* 31, 13272–
545 13280. doi:10.1523/JNEUROSCI.3337-11.2011.
- 546 Chu, P.-C., Liu, H.-L., Lai, H.-Y., Lin, C.-Y., Tsai, H.-C., and Pei, Y.-C. (2015). Neuromodulation
547 accompanying focused ultrasound-induced blood-brain barrier opening. *Sci Rep* 5, 15477.
548 doi:10.1038/srep15477.
- 549 Deán-Ben, X. L., Sela, G., Lauri, A., Kneipp, M., Ntziachristos, V., Westmeyer, G. G., et al. (2016).
550 Functional optoacoustic neuro-tomography for scalable whole-brain monitoring of calcium
551 indicators. *Light Sci Appl* 5, e16201–7. doi:10.1038/lsa.2016.201.
- 552 Devor, A., Sakadžić, S., Srinivasan, V. J., Yaseen, M. A., Nizar, K., Saisan, P. A., et al. (2012).
553 Frontiers in optical imaging of cerebral blood flow and metabolism. *J. Cereb. Blood Flow Metab.*
554 32, 1259–1276. doi:10.1038/jcbfm.2011.195.
- 555 Friston, K. J. (2009). Modalities, Modes, and Models in Functional Neuroimaging. *Science* 326, 399–
556 403. doi:10.1126/science.1174521.
- 557 Goldman, H., Berman, R. F., Hazlett, H., and Murphy, S. (1992). Cerebrovascular responses to
558 pentylenetetrazol: time and dose dependent effects. *Epilepsy Res.* 12, 227–242.
- 559 Goss-Sampson, M. A., and Kriss, A. (1991). Effects of pentobarbital and ketamine-xylazine
560 anaesthesia on somatosensory, brainstem auditory and peripheral sensory-motor responses in the
561 rat. *Lab. Anim.* 25, 360–366. doi:10.1258/002367791780810074.
- 562 Heo, C., Park, H., Kim, Y.-T., Baeg, E., Kim, Y. H., Kim, S.-G., et al. (2016). A soft, transparent,
563 freely accessible cranial window for chronic imaging and electrophysiology. *Sci Rep* 6, 27818.
564 doi:10.1038/srep27818.

- 565 Hillman, E. M. C. (2007). Optical brain imaging in vivo: techniques and applications from animal to
566 man. *J. Biomed. Opt.* 12, 051402–051402–28. doi:10.1117/1.2789693.
- 567 Hoshi, Y., and Tamura, M. (1993). Dynamic changes in cerebral oxygenation in chemically induced
568 seizures in rats: study by near-infrared spectrophotometry. *Brain Res.* 603, 215–221.
- 569 Jacques, S. L., and Prahl, S. (2013). *Extinction coefficient of melanin*. OMLC
570 (<https://omlc.org/spectra/melanin/extcoeff.html>).
- 571 Johnston, M. V., Ammanuel, S., O'Driscoll, C., Wozniak, A., Naidu, S., and Kadam, S. D. (2014).
572 Twenty-four hour quantitative-EEG and in-vivo glutamate biosensor detects activity and
573 circadian rhythm dependent biomarkers of pathogenesis in *Mecp2* null mice. *Front Syst Neurosci*
574 8, 118. doi:10.3389/fnsys.2014.00118.
- 575 Jurkat-Rott, K., and Lehmann-Hom, F. (2004). The patch clamp technique in ion channel research.
576 *Current Pharmaceutical Biotechnology* 5, 387–395. doi:10.2174/1389201043376715.
- 577 Kang, J., Boctor, E. M., Adams, S., Kulikowicz, E., Zhang, H. K., Koehler, R. C., et al. (2018a).
578 Validation of noninvasive photoacoustic measurements of sagittal sinus oxyhemoglobin
579 saturation in hypoxic neonatal piglets. *J Appl Physiol* 125, 983–989.
580 doi:10.1152/jappphysiol.00184.2018.
- 581 Kang, J., Kadam, S. D., Elmore, J. S., Sullivan, B. J., Valentine, H., Malla, A. P., et al. (2018b).
582 Transcranial photoacoustic imaging of NMDA-evoked focal circuit dynamics in rat forebrain.
583 *bioRxiv* 308585, 1–26. doi:10.1101/308585.
- 584 Lewis, P. M., Thomson, R. H., Rosenfeld, J. V., and Fitzgerald, P. B. (2016). Brain Neuromodulation
585 Techniques: A Review. *Neuroscientist* 22, 1073858416646707–421.
586 doi:10.1177/1073858416646707.
- 587 Li, W., Chen, R., Lv, J., Wang, H., Liu, Y., Peng, Y., et al. (2018). In Vivo Photoacoustic Imaging of
588 Brain Injury and Rehabilitation by High-Efficient Near-Infrared Dye Labeled Mesenchymal
589 Stem Cells with Enhanced Brain Barrier Permeability. *Adv Sci (Weinh)* 5, 1700277–11.
590 doi:10.1002/advs.201700277.
- 591 Logothetis, N. K. (2008). What we can do and what we cannot do with fMRI - ProQuest. *Nature*.
- 592 Löscher, W. (2017). Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the
593 Discovery of Antiseizure Drugs. *Neurochem. Res.* 42, 1873–1888. doi:10.1007/s11064-017-
594 2222-z.
- 595 Martišienė, I., Mačianskienė, R., Treinys, R., Navalinskas, A., Almanaitytė, M., Karčiauskas, D., et
596 al. (2016). Voltage-Sensitive Fluorescence of Indocyanine Green in the Heart. *BPJ* 110, 723–
597 732. doi:10.1016/j.bpj.2015.12.021.
- 598 Mazur, F., Bally, M., Städler, B., and Chandrawati, R. (2017). Liposomes and lipid bilayers in
599 biosensors. *Advances in Colloid and Interface Science* 249, 88–99.
600 doi:10.1016/j.cis.2017.05.020.

- 601 Nehlig, A., Vergnes, M., Waydelich, R., Hirsch, E., Charbonne, R., Marescaux, C., et al. (1996).
602 Absence seizures induce a decrease in cerebral blood flow: Human and animal data. *J. Cereb.*
603 *Blood Flow Metab.* 16, 147–155.
- 604 Nie, L., Cai, X., Maslov, K., Garcia-Urbe, A., Anastasio, M. A., and Wang, L. V. (2012).
605 Photoacoustic tomography through a whole adult human skull with a photon recycler. *J. Biomed.*
606 *Opt.* 17, 110506. doi:10.1117/1.JBO.17.11.110506.
- 607 Nowak, K., Mix, E., Nowak, K., Strauss, U., Gimsa, J., Benecke, R., et al. (2011). Optimizing a
608 Rodent Model of Parkinson's Disease for Exploring the Effects and Mechanisms of Deep Brain
609 Stimulation. *Parkinson's Disease* 2011, 1–19. doi:10.4061/2011/414682.
- 610 Ordek, G., Groth, J. D., and Sahin, M. (2013). Differential effects of ketamine/xylazine anesthesia on
611 the cerebral and cerebellar cortical activities in the rat. *Journal of Neurophysiology* 109, 1435–
612 1443. doi:10.1152/jn.00455.2012.
- 613 Pak, R. W., Kang, J., Valentine, H., Loew, L. M., Thorek, D. L., Boctor, E. M., et al. (2018).
614 Voltage-sensitive dye delivery through the blood brain barrier using adenosine receptor agonist
615 Regadenoson. *Biomed. Opt. Express* 9, 3915–3922. doi:doi.org/10.1364/boe.9.003915.
- 616 Paxinos, G., and Watson, C. (2014). *The Rat Brain in Stereotaxic Coordinates*. Seventh edition.
617 Elsevier Academic Press Available at:
618 <https://books.google.com/books?id=FuqGAWAAQBAJ&printsec=frontcover#v=onepage&q&f=false>
619 false.
- 620 Paxton, W. F., McAninch, P. T., Achyuthan, K. E., Shin, S. H. R., and Monteith, H. L. (2017).
621 Monitoring and modulating ion traffic in hybrid lipid/polymer vesicles. *Colloids and Surfaces B:*
622 *Biointerfaces* 159, 268–276. doi:10.1016/j.colsurfb.2017.07.091.
- 623 Raichle, M. E. (1998). Behind the scenes of functional brain imaging: a historical and physiological
624 perspective. *Proc. Natl. Acad. Sci. U.S.A.* 95, 765–772. doi:10.1073/pnas.95.3.765.
- 625 Raichle, M. E., and Mintun, M. A. (2006). Brain work and brain imaging. *Annu. Rev. Neurosci.* 29,
626 449–476. doi:10.1146/annurev.neuro.29.051605.112819.
- 627 Ramnath, R. R., Strange, K., and Rosenberg, P. A. (1992). Neuronal injury evoked by depolarizing
628 agents in rat cortical cultures. *Neurosci Res* 51, 931–939.
- 629 Rosilio, V. (2018). How Can Artificial Lipid Models Mimic the Complexity of Molecule–Membrane
630 Interactions? *Advances in Biomembranes and Lipid Self-Assembly*.
- 631 Ruo, B., Zhang, R., Li, L., Shao, J.-Y., and Wang, L. V. (2017). Photoacoustic imaging of voltage
632 responses beyond the optical diffusion limit. *Sci Rep* 7, 2560. doi:10.1038/s41598-017-02458-w.
- 633 Siemen, H., Colas, D., Heller, H. C., Brüstle, O., and Pera, R. A. R. (2011). Pumilio-2 function in the
634 mouse nervous system. *PLoS ONE* 6, e25932. doi:10.1371/journal.pone.0025932.
- 635 Sigal, I., Koletar, M. M., Ringuette, D., Gad, R., Jeffrey, M., Carlen, P. L., et al. (2016). Imaging
636 brain activity during seizures in freely behaving rats using a miniature multi-modal imaging
637 system. *Biomed. Opt. Express* 7, 3596–14. doi:10.1364/BOE.7.003596.

- 638 Strangman, G. E., Li, Z., and Zhang, Q. (2013). Depth sensitivity and source-detector separations for
639 near infrared spectroscopy based on the Colin27 brain template. *PLoS ONE* 8, e66319.
640 doi:10.1371/journal.pone.0066319.
- 641 Takahashi, M., Liou, S. Y., and Kuniyama, M. (1995). Ca²⁺- and Cl⁻-dependent, NMDA receptor-
642 mediated neuronal death induced by depolarization in rat hippocampal organotypic cultures.
643 *Brain Res.* 675, 249–256.
- 644 Torricelli, A., Contini, D., Pifferi, A., Caffini, M., Re, R., Zucchelli, L., et al. (2014). Time domain
645 functional NIRS imaging for human brain mapping. *NeuroImage* 85 Pt 1, 28–50.
646 doi:10.1016/j.neuroimage.2013.05.106.
- 647 Treger, J. S., Priest, M. F., Iezzi, R., and Bezanilla, F. (2014). Real-time imaging of electrical signals
648 with an infrared FDA-approved dye. *Biophysj* 107, L09–L12. doi:10.1016/j.bpj.2014.07.054.
- 649 Tufail, Y., Yoshihiro, A., Pati, S., Li, M. M., and Tyler, W. J. (2011). Ultrasonic neuromodulation by
650 brain stimulation with transcranial ultrasound. *Nat Protoc* 6, 1453–1470.
651 doi:10.1038/nprot.2011.371.
- 652 Vanitha, N. V. (2011). Positron emission tomography in neuroscience research. *ANS* 18, 36.
653 doi:10.5214/ans.0972.7531.1118202.
- 654 Wang, L. V., and Hu, S. (2012). Photoacoustic tomography: in vivo imaging from organelles to
655 organs. *Science* 335, 1458–1462. doi:10.1126/science.1216210.
- 656 Wang, X., Pang, Y., Ku, G., Xie, X., Stoica, G., and Wang, L. V. (2003). Noninvasive laser-induced
657 photoacoustic tomography for structural and functional in vivo imaging of the brain. *Nat*
658 *Biotechnol* 21, 803–806. doi:10.1038/nbt839.
- 659 Zhang, H. K., Yan, P., Kang, J., Abou, D. S., Le, H. N. D., Jha, A. K., et al. (2017). Listening to
660 membrane potential: photoacoustic voltage-sensitive dye recording. *J. Biomed. Opt.* 22, 045006.
661 doi:10.1117/1.JBO.22.4.045006.
- 662 Zhang, M. Q., Sun, D. N., Xie, Y. Y., Peng, G. Y., Xia, J., Long, H. Y., et al. (2014a). Three-
663 dimensional visualization of rat brain microvasculature following permanent focal ischaemia by
664 synchrotron radiation. *BJR* 87, 20130670–8. doi:10.1259/bjr.20130670.
- 665 Zhang, T., Zhou, J., Jiang, R., Yang, H., Carney, P. R., and Jiang, H. (2014b). Pre-seizure state
666 identified by diffuse optical tomography. *Sci Rep* 4, 113–10. doi:10.1038/srep03798.